Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic Review

Clinical Infectious Diseases

Volumn 37, Issue 7, 2003, Pages 959-972

  Rhew, David C ^a,b,c   Bernal, Myriam ^b   Aguilar, Daniel ^b   Iloeje, Uchenna ^d   Goetz, Matthew Bidwell ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Zynx Health   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; LIPOPROTEIN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DISEASE ASSOCIATION; EVALUATION; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MEDICAL LITERATURE; MORPHOLOGICAL TRAIT; OBSERVATION; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPOPROTEINS; RISK FACTORS;

EID: 0142043954     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378064     Document Type: Article

References (93)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus-infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
4. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000; 23:261-5.
5. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160:2050-6.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
7. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
8. Torre D, Orofino G, Gennero L, Pugliese A. Ischemic cardiovascular disease in patients with HIV-1 infection treated with HAART [abstract 806]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2002.
9. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002; 34:98-102.
10. Negredo E, Martinez-Picado J, Ruiz L, et al. SWATCH Study: a multicenter trial of proactive treatment switching - results at 48 weeks of follow-up [abstract I-672]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2001.
11. Matheron S, Massip P, Trepo C, et al. Metabolic and clinical evaluation of lipodystrophy syndrome (LD) in HIV-1-infected adults receiving initial HAART with or without a protease inhibitor (PI): 48-week data from the CNAF3007 Study [abstract 670-]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
12. Bozzette SA, Ake C, Carpenter A, et al. Cardio- and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US veterans [abstract LB-9]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
13. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
14. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24:416-20.
15. Moyle G, Baldwin C. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: a cross-sectional analysis [abstract 054]. In: Program and abstracts of the 1st International Workshop on Adverse Reactions and Lipodystrophy in HIV. 1999.
16. Walmsley S, Montaner J, Saag M, Hill A, Barylski C, Chen K. Nucleoside reverse transcriptase inhibitor treatment as a risk factor for hyperlipidaemia: results from the FOCUS trial [abstract 052]. In: Program and abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2002.
17. Polo R, Verdejo J, Martinez-Rodriguez S, Madrigal P, Gonzalez-Munoz M. Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2000; 25:284-6.
18. Galli M, Gervasoni C, Adorni F, et al. Factors associated with the development of high serum triglyceride levels in patients receiving two NRTI combinations [abstract 40]. In: Program and abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2002.
19. Gallant J, Staszewski S, Pozniak A, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naive patients: a 48 week interim analysis [abstract LB-2]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2002.
20. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-32.
21. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:21-31.
22. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr 2000; 24:310-5.
23. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men [abstract 657]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
24. Holmberg SD, Moorman AC, Tong TC, et al. Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV-infected patients [abstract TuPeB4494]. In: Program and abstracts of the 14th International AIDS Conference. Stockholm: International AIDS Society, 2002.
25. Justman J, Dancff A, Benning L, et al. Association of diabetes and protease inhibitor use in a large natural history cohort of HIV+ women [abstract 661]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
26. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-7.
27. d'Arminio Monforte A, Bugarini R, Pezzotti PS, et al. Changes in triglycerides and cholesterol in response to HAART in Italian Cohort Naive Antiretroviral (ICONA) [abstract WePeB4242]. In: Program and abstracts of the 13th International AIDS Conference. Stockholm: International AIDS Society, 2000.
28. Katlama C, Fenske S, Gazzard B, Lazzarin A, Beauvais L. Switch to trizivir versus continued HAART provides equivalent HIV-1 RNA suppression at 48 weeks (TRIZAL-AZL30002) [abstract I-671]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2001.
29. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective study of hyperlipidemia in ART-naive subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002) [abstract 33]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
30. Montaner JSG, Saag MS, Barylski C, Siemon-Hryczyk P. FOCUS Study: saquinavir QD regimen versus efavirenz qd regimen 48 week analysis in HIV infected patients [abstract H-167]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2002.
31. Rozenbaum W, Delfraissy JF, Bentata M, DeTruchis P, Antoun Z. Metabolic and clinical evaluation of lipodystrophy 48 weeks after switching from two nucleoside reverse transcriptase inhibitors/protease inhibitor to two nucleoside reverse transcriptase inhibitors/abacavir (French Substudy, CNA30017) [abstract P89]. In: Program and abstracts of the 2nd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2000.
32. van der Valk M, Kastelein JJP, Murphy RL, A et al. Rise in HDL-cholesterol associated with nevirapine-containing antiretroviral therapy in HIV-1-infected patients is sustained over 96 weeks of treatment [abstract 123]. In: Program and abstracts of the 3rd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2001.
33. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavirbased triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15:1517-26.
34. Garcia F, Romeu J, Grau I, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 1999; 13:2377-88.
35. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34:504-10.
36. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6:413-21.
37. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27:229-36.
38. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-60.
39. van Leth F, Friis-Moller N, Weber R, et al. Distinguishable lipid profiles between PI and NNRTI therapy may carry different risk of cardiovascular disease (CVD) [abstract 34]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
40. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-8.
41. Stein JH, Klein MA, Belleliumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-62.
42. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001; 12:463-8.
43. Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86:296-302.
44. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-7.
45. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS 2000; 11:451-5.
46. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34:55-63.
47. Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144:642-8.
48. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002; 30:440-7.
49. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-8.
50. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-5.
51. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
52. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
53. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27:77-81.
54. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-73.
55. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162:433-8.
56. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-7.
57. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1396-405.
58. Sosman JM, Klein MA, Bellehumeur JL, Aeschlimann SE, Stein JH. Endothelial dysfunction is associated with the use of human immunodeficiency virus-1 protease inhibitors [abstract 29]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
59. Hewitt RG, Thompson WM, Chu A, Hernandez F, Shelton MJ. Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy [abstract 658]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
60. Boufassa F, Dulioust A, Lascaux AS, Bodart L, Goujard C. Lipodystrophy and metabolic disorders in 646 HIV-1 infected patients previously treated with or without a protease inhibitor (PI) [abstract 17]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
61. Trape L, Lupo S, Agostini M, Palazzi J, Suarez C, Laurello D. Incidence of lypodistrophy and dislipemic disorders in HIV+ patients on HAART [abstract WePeB4281]. In: Program and abstracts of the 13th International AIDS Conference. Stockholm: International AIDS Society, 2000.
62. Seminari E, Pan A, Voltini G, et al. Heamostatic markers of cardiovascular risk in HIV patients treated and untreated with protease inhibitors (PIs) [abstract ThOrB760]. In: Program and abstracts of the 13th International AIDS Conference. Stockholm: International AIDS Society, 2000.
63. Talwani R, Falusi OM, Mendes de Leon CF, et al. Electron beam computed tomography (EBCT) for assessment of coronary artery disease (CAD) in HIV infected males on antiretroviral therapy (ART) [abstract 1299]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2000.
64. Walli RK, Michl GM, Segerer S, et al. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors [abstract 645]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
65. Thiebaut R, Malvy D, Mercie P, Daucourt V, Marimoutou C, Dabis F. Factors influencing the evolution of plasma triglyceride in the era of HAART, Aquitaine Cohort, 1996-1998 [abstract 015]. In: Program and abstracts of the 1st International Workshop on Adverse Reactions and Lipodystrophy in HIV. 1999.
66. Pan A, Seminari E, Voltini G, et al. Intima media thickness as cardiovascular risk marker in HIV-positive patients treated and untreated with protease inhibitors [abstract 025]. In: Program and abstracts of the 2nd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2000.
67. Walli R, Huster K, Bogner JR, Goebel FD. Effect of switching from protease inhibitors to abacavir on insulin sensitivity and fasting lipids: 12-month follow-up [abstract P43]. In: Program and abstracts of the 2nd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2000.
68. Brown T, Timpone J, Ruppe M, et al. Bone loss associated with abnormalities in glucose metabolism in HIV patients on protease inhibitors (PIs) [abstract 716-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
69. Arrizabalaga J, Rodriguez J, von Wichmann MA, et al. Incidence rate of lipid abnormalities in patients on their first highly active antiretroviral therapy (HAART) [abstract B10650]. In: Program and abstracts of the 14th International AIDS Conference, 2002.
70. Mallon PWG, Miller J, Carr A, Cooper D. Analysis of changes in metabolic and morphological abnormalities in HIV-positive individuals, with HIV-associated lipodystrophy, changing regimens [abstract 83]. In: Program and abstracts of the 3rd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2001.
71. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12:1645-51.
72. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15:1811-22.
73. Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32:367-72.
74. Velasco M, Tellez MJ, Perez-Cecilia E, Gamir MJ, Estrada V, Roca V. Clinical impact of HIV protease inhibitor therapy on 98 HIV-patients after 1 year of follow-up [abstract 1-223]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.
75. Chrysos G, Mangafas N, Bilianou H, et al. The effects of antiretroviral treatment with protease inhibitors (PIs) on serum lipids in HIV infected patients [abstract]. In: Program and abstracts of the 71st Congress of the European Atherosclerosis Society. 1999.
76. Bentata-Pessayre M, Mosnier A, Berlureau P, et al. Metabolic and morphologic tolerability of nevirapine in naive or pre-treated HIV 1 infected patients [abstract WePeB4202]. In: Program and abstracts of the 13th International AIDS Conference. Stockholm: International AIDS Society, 2000.
77. Gomez F, Selma D, Cousinuo M, Trouillhet I, Bernal JA, Mollina FJ. Arterial hypertension associated to HAART-induced metabolic alterations [abstract WePeB4218]. In: Program and abstracts of the 13th International AIDS Conference. Stockholm: International AIDS Society, 2000.
78. Blanco F, Casimiro C, Gomez F, et al. Metabolic outcome (lipid profile and lipodystrophy body shape changes) in HIV-positive patients after switching PI to NNRTI [abstract P14]. In: Program and abstracts of the 2nd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2000.
79. Bickel M, Rickerts V, Jacobi V et al. Evolution of fasting metabolic parameters and fat distribution after switching protease inhibitor in the PROTRA study [abstract P90]. In: Program and abstracts of the 2nd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2000.
80. Lenormand-Walckenaer C, Cazaubon M, Joly V, et al. Carotid intima media thickness in protease inhibitor-treated HIV-1 infected patients with hyperlipemia [abstract 1298]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2000.
81. + persons [abstract 1533]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2000.
82. Estrada V, De Villar NGP, Martinez-Larrad T, Tellez MJ, Serrano-Rios M. Switching to efavirenz from protease inhibitor-based therapy does not improve insulin resistance after one year in HIV patients with lipodystrophy syndrome [abstract 671]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
83. Casado JL, Arrizabalaga J, Antela A, et al. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: a 52-week, multicenter, prospective study [abstract 673]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
84. Koppel K, Bratt G, Sandstrom E. The development of laboratory cardiovascular risk factors in patients on highly active antiretroviral therapy during 24 months follow-up [abstract 75]. In: Program and abstracts of the 3rd International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2001.
85. Fumero E, Fisac C, Crespo M, et al. Metabolic and body composition changes in patients switching from a protease inhibitor-containing regimen to abacavir (ABC), efavirenz (EFV) or nevirapine (NVP): twelve-month results of a randomized study (LIPNEFA) [abstract ThPeB7354]. In: Program and abstracts of the 14th International AIDS Conference. Stockholm: International AIDS Society, 2002.
86. Quirino T, Bonfanti P, Faggion I, et al. Glucose metabolism abnormalities associated with highly active anti-retroviral therapy, a cohort study [abstract 35]. In: Program and abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2002.
87. Walmsley S, Foster A, Raboud J, et al. A prospective study of body fat redistribution and metabolic abnormalities in patients initiating highly active antiretroviral therapy [abstract 82]. In: Program and abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2002.
88. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature. XIX. Applying clinical trial results B: guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282:1371-7.
89. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. New York: Wiley, 2000.
90. Sanne I, Cahn P, Percival L, et al. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naive HIV(+) patients (AI424-008) [abstract 1-667]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2001.
91. Murphy J, Thiry A, Mancini M, Pakrovsky V, Rozenbaum W. Twelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidemia: results from BMS AI424-044 [abstract 15]. In: Program and abstracts of the 4th International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2001.
92. Sension M, Thiry A, Giordano M. Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily each with fixed-dose zidovudine plus lamivudine [abstract 36]. In: Program and abstracts of the 4th International Workshop on Adverse Reactions and Lipodystrophy in HIV. 2001.
93. Currier J, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals: associations with antiretroviral therapy [abstract 54]. In: Program and abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2002.